NT_1170x120_1-11-18

LLC

US WorldMeds and Salix announce U.S. roll out of Lucemyra

US WorldMeds and Salix announce U.S. roll out of Lucemyra

LOUISVILLE, K.Y. and BIDGEWATER, N.J. – US WorldMeds, LLC, and Salix Pharmaceuticals, a wholly owned subsidiary of Bausch Health Companies Inc., today announced the U.S. launch and availability of Lucemyra (lofexidine) 0.18 mg tablets, the first and only non-opioid medication indicated for mitigation of opioid withdrawal symptoms to facilitate abrupt opioid discontinuation in adults. The Centers

New report from HDA looks at reverse distribution of pharmaceuticals

New report from HDA looks at reverse distribution of pharmaceuticals

ARLINGTON, Va.— A new report published by the HDA Research Foundation entitled The Role of Reverse Distribution provides insights into the reverse distribution of pharmaceutical products. The Foundation estimates that this channel accounts for 3.5 to 4% of all pharmaceutical sales — more than 120 million product units — and exceeds $13 billion in product value. Reverse distribution

Viactiv launches chocolate digestive health chews

Viactiv launches chocolate digestive health chews

LAWRENCEVILLE, N.J. — Adare Pharmaceuticals’ consumer products subsidiary (Activ Nutritional, LLC), has launched new Viactiv Digestive Health Soft Chews, expanding the Viactiv supplement brand into the growing digestive health category. New Viactiv Digestive Health are said to be the only 2-in-1 supplement to combine a probiotic-derived, clinically-studied strain that helps feed good bacteria and fight bad bacteria to

Upsher-Smith releases Doxazosin tablets

Upsher-Smith releases Doxazosin tablets

MAPLE GROVE, Minn. — Upsher-Smith Laboratories, LLC (Upsher-Smith) announced the launch of Doxazosin tablets, USP, 1 mg, 2 mg, 4 mg and 8 mg. The product was approved by the U.S. Food and Drug Administration (FDA) on April 17, 2018. Upsher-Smith’s Doxazosin tablets are an AB-rated generic version of the branded product, Cardura (doxazosin mesylate